Efficacy and Safety of Aidi Injection Combined with Transcatheter Arterial Chemoembolization on Primary Hepatic Carcinoma: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the 22 included studies.

First author, year	Sample size; (E/C)	Age(E/C)	Stage	Intervention^†; (E/C)	Treatment; course (C/W/D)	KPS	Outcome
Wang T, 2004	35/34	65.8/66.7	II-III	ADI+TACE(MEF)	1C, 30D/C	>60	①②⑤
Tan XY, 2005	33/30	38	-	ADI+TACE(DM“E-A/L”F)	2C, 30-40D/C	≥60	①②⑤
Li RJ, 2005	32/30	53	-	ADI+TACE(DELF)	2C, 3-4W/C	≥60	①②⑤
Ma T, 2005	36/29	50/52	I-III	ADI+TACE(DHLF)	2C, 3-4W/C	>60	①②⑤
Liu RC, 2005	16/19	52/49	I-III	ADI+TACE(DALF)	2C, 4-5W/C	>60	①②⑤
Yang JM, 2006	31/31	49	-	ADI+TACE(DELF)	2C, 4-12W/C	-	①②
Wang QP, 2006	25/23	50.1	-	ADI+TACE(M“A/E”LF)	3C, 4-5W/C	-	①②③④⑤
Ma BQ, 2007	60/60	44	-	ADI+TACE(DCMLF)	3C, 35D/C	≥60	①②④⑤
Dong HT, 2007	33/32	56.3/56.7	II-IV	ADI+TACE(TLF)	2C, 28D/C	≥60	①②⑤
Chen SC, 2007	32/28	36-70	-	ADI+TACE(MOLF)	2-6C, 4-6W/C	>60	①②④
Gou AL, 2008	27/27	49	-	ADI+TACE(DELF)	2C, 4-12W/C	-	①②
Meng SX, 2008	75/73	55.2/56.8	II-IV	ADI+TACE(TLF)	2C, 2W/C	>60	①②③⑤
Yang J, 2008	20/20	28-74	-	ADI+TACE(D“A/M”LF)	2-3C, 28D/C	>40	①②⑤
Dong HT, 2008	46/46	56±3/55.7±3	II-IV	ADI+TACE(HLF)	2C, 28D/C	>60	①②③⑤
Huang J, 2009	30/30	45.22/44.98	-	ADI+TACE(DELF)	2C, 3D/C	30-60	①②
Zhan GQ, 2010	32/26	43.6	II-III	ADI+TACE(MHELF)	2C, 3-4W/C	>50	①②③⑤
Yang ZJ, 2011	30/30	49.8/49	-	ADI+TACE(M“H/E”LF)	3C, 4-6W/C	≥70	①②③④
Li HF, 2011	36/32	52±4	-	ADI+TACE(MTLF)	1C, 12W/C	≥70	①②
A YX, 2011	54/54	56.3/55.7	II-IV	ADI+TACE(HLF)	2C, 28D/C	≥60	①②③⑤
Zhang GS, 2012	47/47	57.1±3/56.7±3	II-IV	ADI+TACE(HLF)	2C, 28D/C	≥60	①②③⑤
Zhu JB, 2012	50/50	35-75	-	ADI+TACE(OLT)	2-5C, 4-6W/C	>60	①②
Sun ZQ, 2012	40/40	56.2	-	ADI+TACE(OHEL)	2-4C, 4-6W/C	-	①②

Note: E/C: experimental group/control group; C: cycle; W: week; D: day; KPS: Karnofsky; intervention: TACE (transcatheter arterial chemoembolization); ADI: Aidi injection; M: MMC (mitomycin); E: EPI (epirubicin); F: 5-FU (5-fluorouracil); A: ADM (adriamycin); L: LUF (lipiodol ultra fluid); D: DDP (cisplatin); H: HCPT (hydroxycamptothecin); T: THP (tetrahydropyranyl); C: CF (calcium folinate); O: OXA (oxaliplatin); outcome: ①clinical response rate; ②KPS; ③survival rate; ④immune function; and ⑤adverse effects. ^†The experiment group was treated with ADI and TACE, and control group was treated with TACE alone.